Linghan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linghan Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Huipei Gan
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications - Jingru Wang
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications - Jinna Lin
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications Liang Jin
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications- Lok Lam Wong
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications Mengdi Zhu
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Cell Death & Disease
UBE2T upregulation underlies the metastasis-associated chemoresistance of breast cancer that can be reversed by BET inhibitors
Most primary breast cancers are sensitive to chemotherapy and some of them can achieve pathological complete response (pCR) by neoadjuvant chemotherapy. However, metastatic breast cancers are almost impossible to reach pCR with chemotherapy and thus are incurable diseases. The mechanisms of metastasis-associated chemoresistance remain poorly understood. Using paired primary and metastatic triple-negative breast cancer (TNBC) models, we identify that UBE2T is responsible for metastasis-associated chemoresistance by promoting PHLPP ubiquitination and AKT phosphorylation, enhancing tumor stemness in metastatic breast cancer. Overexpressed NFYA is the transcription factor that upregulates UBE2T expression. Analysis of clinical samples shows that the NFYA/UBE2T/p-AKT axis was highly activated in metastatic breast cancer. More importantly, bromodomain and extraterminal domain proteins (BET) inhibitors are found to significantly reduce UBE2T transcription, restoring the sensitivity of metastatic breast cancer to chemotherapy both in vitro and in vivo. These findings suggest that BET inhibitors could reverse the metastasis-associated chemoresistance by targeting aberrantly upregulated NFYA/UBE2T/p-AKT pathway in metastatic breast cancer, particularly in TNBC.
- 4 November 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessUBE2T upregulation underlies the metastasis-associated chemoresistance of breast cancer that can be reversed by BET inhibitors
Most primary breast cancers are sensitive to chemotherapy and some of them can achieve pathological complete response (pCR) by neoadjuvant chemotherapy. However, metastatic breast cancers are almost impossible to reach pCR with chemotherapy and thus are incurable diseases. The mechanisms of metastasis-associated chemoresistance remain poorly understood. Using paired primary and metastatic triple-negative breast cancer (TNBC) models, we identify that UBE2T is responsible for metastasis-associated chemoresistance by promoting PHLPP ubiquitination and AKT phosphorylation, enhancing tumor stemness in metastatic breast cancer. Overexpressed NFYA is the transcription factor that upregulates UBE2T expression. Analysis of clinical samples shows that the NFYA/UBE2T/p-AKT axis was highly activated in metastatic breast cancer. More importantly, bromodomain and extraterminal domain proteins (BET) inhibitors are found to significantly reduce UBE2T transcription, restoring the sensitivity of metastatic breast cancer to chemotherapy both in vitro and in vivo. These findings suggest that BET inhibitors could reverse the metastasis-associated chemoresistance by targeting aberrantly upregulated NFYA/UBE2T/p-AKT pathway in metastatic breast cancer, particularly in TNBC.
- Open Access
- 4 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil
5-Fluorouracil (5-FU) and its prodrugs are widely used drugs for chemotherapy in various cancers. However, their effectiveness in breast cancer is limited. mTORC1 pathway, as a known mediator of therapy resistance in breast cancer, presents a compelling target for combination approaches. This study investigated the mTORC1 inhibitor everolimus as a sensitizer to 5-FU and capecitabine in breast cancer, exploring thymidylate synthase (the direct target of 5-FU) as a predictive biomarker and targeted mechanism. Our results demonstrate that everolimus significantly enhances 5-FU efficacy in HER2-negative breast cancer in vivo and in vitro. Mechanistically, everolimus downregulates thymidylate synthase (TYMS) by inducing its proteasomal degradation through a ubiquitination-independent way involving downregulation of O-GlcNAc transferase (OGT) and a reduced O-GlcNAcylation of TYMS, which destabilizes TYMS homodimer. Overexpression of OGT reversed TYMS degradation. Importantly, this combination strategy was effective in refractory breast cancer patients, and decreased levels of TYMS and OGT were observed in breast cancer patient specimens collected before and after everolimus-containing treatment. In conclusion, our study reveals that everolimus sensitizes breast cancer to fluoropyrimidines by destabilizing TYMS through modulation of its O-GlcNAcylation. These findings support a promising combination strategy to improve the therapeutic efficacy of 5-FU and capecitabine in breast cancer.
- 4 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessEverolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil
5-Fluorouracil (5-FU) and its prodrugs are widely used drugs for chemotherapy in various cancers. However, their effectiveness in breast cancer is limited. mTORC1 pathway, as a known mediator of therapy resistance in breast cancer, presents a compelling target for combination approaches. This study investigated the mTORC1 inhibitor everolimus as a sensitizer to 5-FU and capecitabine in breast cancer, exploring thymidylate synthase (the direct target of 5-FU) as a predictive biomarker and targeted mechanism. Our results demonstrate that everolimus significantly enhances 5-FU efficacy in HER2-negative breast cancer in vivo and in vitro. Mechanistically, everolimus downregulates thymidylate synthase (TYMS) by inducing its proteasomal degradation through a ubiquitination-independent way involving downregulation of O-GlcNAc transferase (OGT) and a reduced O-GlcNAcylation of TYMS, which destabilizes TYMS homodimer. Overexpression of OGT reversed TYMS degradation. Importantly, this combination strategy was effective in refractory breast cancer patients, and decreased levels of TYMS and OGT were observed in breast cancer patient specimens collected before and after everolimus-containing treatment. In conclusion, our study reveals that everolimus sensitizes breast cancer to fluoropyrimidines by destabilizing TYMS through modulation of its O-GlcNAcylation. These findings support a promising combination strategy to improve the therapeutic efficacy of 5-FU and capecitabine in breast cancer.